| 产品描述: | RS 102895盐酸盐是CKR-2B(CCR2)选择性趋化因子受体拮抗剂(IC 50值为0.36和17.8μM,分别用于抑制人重组CKR-2B和CKR-1(CCR2b和CCR1受体)。分别以32 nM和1.7μM的IC | 50阻滞MCP-1刺激的钙内流和趋化性。抑制α| 1A | -AR,α| 1D | -AR和SR-1A(α1A,α1D和5-HT | 1A |受体)。 |
| 体内研究: |
RS102895 (3 g/L) causes progressive decrease in pain threshold in rats with bone cancer pain (BCP) at day 3-9 after surgery via intrathecal injection, but the pain threshold increases after 12 days. RS102895 also potently reverses the pattern of NR2B, nNOS, and SIGIRR expression in spinal cord. |
| 参考文献: |
1. Mirzadegan T, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem. 2000 Aug 18;275(33):25562-71. 2. Park J, et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am J Physiol Renal Physiol. 2008 Sep;295(3):F749-57. 3. Ren F, et al. Analgesic Effect of Intrathecal Administration of Chemokine Receptor CCR2 Antagonist is Related to Change in Spinal NR2B, nNOS, and SIGIRR Expression in Rat with Bone Cancer Pain. Cell Biochem Biophys. 2015 Jun;72(2):611-6. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.561 ml |
12.807 ml |
25.615 ml |
| 5 mM |
0.512 ml |
2.561 ml |
5.123 ml |
| 10 mM |
0.256 ml |
1.281 ml |
2.561 ml |
| 50 mM |
0.051 ml |
0.256 ml |
0.512 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |